ArticleLeukemia2020
Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 82 citations in OpenAlex.
- Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.Blood advances · 2020Trial
- Modulation of the sensitivity to ruxolitinib-mediated JAK2 inhibition by mutationally activated SHP2 exhibits cell context dependency in pre-clinical models of myeloproliferative neoplasms.bioRxiv : the preprint server for biology · 2026Article
- ARAF mutated langerhans cell histiocytosis developed on the background of ARAF/JAK2 mutated polycythaemia vera: evidence of branching evolution from the same progenitor cell. A case report and literature review.Annals of hematology · 2026Review
- Clonal Metamorphosis: Deconstructing MPN Evolution with Single-Cell and Spatial Multi-Omics.Clinical and experimental medicine · 2026Review
- [External validation and incremental value assessment of the RR6 prognostic model in Chinese myelofibrosis patients treated with ruxolitinib: focusing on overall survival].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Developmental stage modulates the prognostic impact of RAS pathway mutations in AML patients undergoing Allo-HSCT.Annals of hematology · 2025Article
- JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms.Nature communications · 2025Article
- SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms.Clinical lymphoma, myeloma & leukemia · 2025Review
- Polycythaemia vera.Nature reviews. Disease primers · 2025Review
- Pathogenesis and management of high molecular risk myeloproliferative neoplasms.Haematologica · 2025Review
- Myelofibrosis: Timing of Transplantation and Management of Splenomegaly.Advances in experimental medicine and biology · 2025Review
- The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies.Blood and lymphatic cancer : targets and therapy · 2025Review
- JAK Inhibitors for Myelofibrosis: Strengths and Limitations.Current hematologic malignancy reports · 2024Review
- Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes.Blood advances · 2024Article
- Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives.Blood cancer journal · 2024Review
- Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN.Blood advances · 2024Article
- Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.HemaSphere · 2024Article
- Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.Cancers · 2024Review
- Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
Abstract
RAS-pathway mutations are recurrent events in myeloid malignancies. However, there is limited data on the significance of RAS-pathway mutations in patients with myelofibrosis (MF). We analyzed next-generation sequencing data of 16 genes, including RAS-pathway genes, from 723 patients with primary and secondary MF across three international centers and evaluated their significance. N/KRAS variants were present in 6% of patients and were typically sub-clonal (median VAF = 20%) relative to other genes variants. RAS variants were associated with advanced MF features including leukocytosis (p = 0.02), high somatic mutation burden (p < 0.01) and the presence of established "molecular high-risk" (MHR) mutations. MF patients with N/KRAS mutations had shorter 3-year overall survival (OS) (34% vs 58%, p < 0.001) and higher incidence of acute myeloid leukemia at 3 years (18% vs 11%, p = 0.03). In a multivariate Cox model, RAS mutations were associated with decreased OS (HR 1.93, p < 0.001). We created a novel score to predict OS incorporating RAS mutations, and it predicted OS across training and validation cohorts. Patients with intermediate risk/high-risk DIPSS with RAS mutations who received ruxolitinib had a nonsignificant longer 2-year OS relative to those who did not receive ruxolitinib. These data demonstrate the importance of identifying RAS mutations in MF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.